

produced growth of *S. cerevisiae*, either in the presence or in the absence of 5-fluorouracil. The ability of myoinositol to promote growth of *S. cerevisiae* is well known⁴.

When the concentration of 5-fluorouracil was increased in the culture medium from the usual level of $7 \cdot 10^{-8}$ to $10^{-4} M$, myoinositol⁵ no longer was effective in restoring growth. Cytosine⁶ and uracil⁶ were both active under these conditions, with the former significantly more active than the latter. These results in yeast may be related to the role of cytidine diphosphate in the biosynthesis of myoinositol phosphatides in the mammal⁶.

To our knowledge, this is the first report indicating a higher excretion of myoinositol by the new-born infant than by adults. Although work has been done on adult excretion of myoinositol⁷⁻¹², the only report dealing with children is the early observation of KULZ¹³. He concludes that the urine of adults and children with a wide variety of diseases may contain myoinositol. It has been shown that the myoinositol content of fetal blood and fetal fluids is consistently higher than in the mother¹⁴.

Zusammenfassung. Ein aktives Agens im Säuglingsurin, das die Hemmung von *Saccharomyces cerevisiae* durch 5-Fluorouracil verhindert, wurde als Myoinositol identifiziert und generell bei allen Neugeborenen, ebenfalls bei einer Anzahl von Kindern mit allgemeiner Aminoacid-

urie, gefunden. Gesunde Erwachsene zeigten keine nennenswerten Mengen.

J. P. SCHIRMER JR., H. TIECKELMANN,
and R. GUTHRIE

*Department of Chemistry and Department of Pediatrics,
State University of New York at Buffalo
(New York USA), July 27, 1964.*

- ⁴ E. V. EASTCOTT, J. phys. Chem. **32**, 1094 (1928).
- ⁵ 0.01 ml of 0.01 M solution impregnated in a 0.25 inch diameter disc of filter paper (Whatmann 3 MM).
- ⁶ B. W. AGRANOFF, R. M. BRADLEY, and R. O. BRADY, J. biol. Chem. **233**, 1077 (1958).
- ⁷ B. C. JOHNSON, H. H. MITCHELL, and T. S. HAMILTON, J. biol. Chem. **161**, 357 (1945).
- ⁸ P. F. FLUERY, J. E. COURTOIS, and A. L. JOUANNET, Bull. Soc. Chim. Biol. **33**, 1885 (1951).
- ⁹ W. H. DAUGHADAY, J. LARNER, and E. HOUGHTON, J. clin. Invest. **33**, 326 (1954).
- ¹⁰ P. MALANGEAU, Bull. Soc. Chim. Biol. **38**, 729 (1956).
- ¹¹ J. E. COURTOIS, C. HELLEU, P. MALANGEAU, and R. PERLES, Bull. Soc. Chim. Biol. **38**, 1017 (1956).
- ¹² C. HELLEU, Bull. Soc. Chim. Biol. **39**, 633 (1957).
- ¹³ E. KULZ, in C. GERHARDT, *Handbuch der Kinderkrankheiten* (Tübingen, Germany 1878), vol. 3, p. 285.
- ¹⁴ J. D. CAMPLING and D. A. NIXON, J. Physiol. **126**, 71 (1954).

Studies on the Chemical Composition of Streptococcal Co-opsonin

It has been reported recently that absorption of human serum with bentonite results in removal of a non-specific 'co-opsonin', which is necessary for optimal phagocytosis of virulent group A streptococci by polymorphonuclear leucocytes in the presence of type-specific antibodies^{1,2}. Amounts of bentonite which almost completely inactivated the serum opsonic activity did not reduce significantly either complement, properdin, or any of the major components of the complement system. This paper describes attempts to characterize the chemical nature of this co-opsonin. It will be shown that it is distinct from lysozyme, and that it may reside in the serum β -lipoprotein moiety.

Materials and methods. Removal of the co-opsonin: Fresh serum from the same donor (M.W.R.) collected in a fasting state, was used in all experiments. The procedure of co-opsonin absorption has been described in detail in a previous communication³ and will be summarized only briefly. Serum was incubated at 37°C for 20 min with the desired amounts of bentonite. It was then separated by centrifugation ($6800 \times g$ for 30 min at 4°C in a Model-L Spinco ultracentrifuge with a No. 30 rotor head) and stored at -70°C until ready for use. Stock suspensions of bentonite were prepared by adding the dry powder (Bentonite, U.S.P., Fischer, Lot No. 790219) to distilled water in a concentration of 3 mg per ml. Particle dispersion was improved by mixing the suspension in a Waring blender for 1 min. Bentonite in amounts desired for serum absorption was separated from stock suspension by centrifugation ($2800 \times g$ for 30 min).

The phagocytic test: The phagocytic test ('Bactericidal Test') was identical with that employed in previous studies^{1,2}. Overnight Todd-Hewitt broth cultures of a strain of type 6 group A streptococcus (T-6/543) adjusted to the desired concentration, type-specific rabbit anti-serum, fresh human serum (M.W.R.) as source of natural co-opsonins, and autologous polymorphonuclear leucocytes, twice washed in physiologic saline, were employed in all experiments. The degree of phagocytosis was expressed by the 'bactericidal index' (BI), which is determined by the relative inhibition of the growth of the streptococcus in the phagocytic test; i.e.

$$\text{Bactericidal index} = \frac{\text{No. of organisms in the inoculum}}{\text{No. of organisms surviving phagocytosis in the presence of type-specific antibody and test serum}} \times \text{Growth in absence of type-specific antibody}$$

As is apparent, the greater the degree of destruction of streptococci by phagocytosis, the greater the numerical value of the bactericidal index.

Complement titration: Complement titration was carried out to the 50% hemolytic endpoint according to the method of KABAT and MAYER³.

- ¹ G. H. STOLLERMAN, Tr. Assn. Am. Physicians **74**, 225 (1961).
- ² G. H. STOLLERMAN, M. W. RYTEL, and J. ORTIZ, J. exp. Med. **117**, 1 (1963).
- ³ E. A. KABAT and M. M. MAYER, *Experimental Immunochimistry* (Charles C. Thomas Publ. Co., Springfield, Illinois 1961), p. 133.

Properdin titration: The zymosan (Fleischman Lab., Lot No. OB 298) assay, as described by KENT et al.⁴, was utilized.

Lysozyme determination: The lysozyme determination was based on that employed by MYRVIK and WEISER⁵. Commercial reagents, consisting of crystalline egg-white lysozyme (Bacto-lysozyme, Difco, Lot No. 465), and ultraviolet-killed, dried culture of *Micrococcus lysodeikticus* (Bacto-lysozyme substrate, Difco, Lot No. 461-10) were used throughout.

Separation of β -lipoproteins: Density gradient ultracentrifugation was employed. The density of the serum specimen was adjusted to 1.063 by the addition of 28% of potassium bromide. This solution was then centrifuged for 20 h at 105,500 $\times g$ in Model-L Spinco ultracentrifuge, in a No. 30 rotor head, at 4°C. The top 1 ml containing all lipoproteins with densities less than 1.063 g/ml was carefully separated. The resultant two fractions were dialyzed in distilled water for 24 h in the cold. The fractions were then concentrated in polyvinyl pyrrolidone to their original volumes.

Determination of β -lipoproteins: A quantitative immunoprecipitation method employing specific anti- β -lipoprotein antibodies (β -L Test, Hyland Lab., Lot No. 371 ITI), was utilized⁶. One drop of test serum was mixed with 2 drops of antiserum, and the resultant mixture drawn into a capillary tube whose one end was then sealed by flame. After a 15 min incubation at room temperature, the capillary tubes were centrifuged for 10 min. The results were expressed in terms of the 'immunocrit', which was derived from the following relationship:

$$\text{Immunocrit} = \frac{\text{length of column of precipitate}}{\text{length of column of precipitate and supernatant}} \times 100.$$

The average immunocrit in 30 healthy young males was found to be 4.11 with a standard deviation of ± 0.42 .

Electrophoresis: Standard paper-strip electrophoretic procedures utilizing Spinco equipment and reagents were employed⁷.

Results. Absorptions of serum with bentonite resulted in an almost complete removal of streptococcal co-opsonins (Table). Even when as little as 0.5 mg of bentonite per ml of serum was used, the bactericidal index diminished from 1240 to 6. There was no significant decrease in the levels of complement or properdin with this amount of bentonite. The β -lipoprotein levels, however, were significantly decreased, and lysozyme activity was completely removed. When amounts of bentonite, in excess of 3 mg, were employed for absorption, complement and properdin could no longer be detected (Table).

Because lysozyme and β -lipoproteins were two of the serum constituents (in addition to the co-opsonin) that were reduced or removed by minute amounts of bentonite, their role in streptococcal phagocytosis was investigated further.

When β -lipoproteins were removed completely from the serum by density gradient ultracentrifugation, the bactericidal index diminished from 2257 to 5. However, recombination of bentonite-absorbed serum with the ultracentrifugal β -lipoprotein fraction did not restore co-opsonin activity of the serum. Addition of purified lysozyme in normal serum concentrations to the bentonite-absorbed serum, similarly failed to re-establish the co-opsonin activity.

Comments. This study confirmed the previously reported selective absorption by bentonite of serum β -lipoproteins⁸, lysozyme⁹, as well as streptococcal co-opsonin^{1,2}. Because of this similar affinity for bentonite, it was considered possible that the co-opsonin activity of the serum may have resided in the β -lipoprotein moiety, or may have been associated with lysozyme.

The reasons for the failure to restore opsonic activity of bentonite-adsorbed serum with purified β -lipoproteins have not been ascertained. Co-opsonins could be extremely labile so that relatively gentle procedures, as have been employed here for the β -lipoprotein isolation, could result in irreversible inactivation. Moreover, other factors distinct from β -lipoproteins, but participating in the opsonic reaction, may have been removed by the bentonite absorption.

Lysozyme has been shown recently to possess a wide antibacterial spectrum when acting in conjunction with specific antibodies and complement¹⁰. Because both antibodies and complement are present under the test conditions of streptococcal phagocytosis, it was thought that lysozyme could participate in the bactericidal reaction, either as the 'co-opsonin' or (more likely) directly as a bacteriolysin. However, restoration of lysozyme activity

⁴ J. F. KENT, A. J. TOUSSANT, and W. A. HOOK, *Proc. Soc. exp. Biol. Med.* **96**, 676 (1957).

⁵ Q. A. MYRVIK and R. S. WEISER, *J. Immunol.* **74**, 9 (1955).

⁶ C. L. HEISKELL, R. T. FISK, W. H. FLORSHEIM, A. TACHI, J. R. GOODMAN, and C. M. CARPENTER, *Am. J. clin. Path.* **35**, 226 (1961).

⁷ R. I. LYTLE, J. YOUNG, and W. T. STILLE, U.S. Naval Medical Research Unit No. 4 Project Report No. MR 005.12-1102.1, to the Bureau of Medicine and Surgery, Navy Department, Washington (D.C. USA), May 2, 1961.

⁸ E. NIKKILA and N. OKER-BLOM, *Science* **116**, 685 (1952).

⁹ E. OSAWA and L. H. MUSCHEL, *J. Immunol.* **84**, 203 (1960).

¹⁰ A. C. WARDLOW, *J. exp. Med.* **114**, 1231 (1962).

Effect of serum absorption with bentonite on the levels of different factors

Serum treated with bentonite ^a	Bactericidal index	Complement (C'H ₅₀ u.)	Properdin (units)	Lysozyme (mcg)	β -lipo-proteins ^b (immunocrit)	γ -globulin %	β -globulin %
Unabsorbed serum	1240	40.9	8	6.8	4.48	10.5	16.6
0.5	6	37.9	8	0	3.51	10.9	15.5
1.5	6	33.6	8	0	3.40	9.8	14.1
3.0	5	0	0	0	3.16	9.1	13.2
6.0	5	0	0	0	2.95	8.6	13.1
12.0	3	0	0	0	2.55	8.9	12.8
24.0	4	0	0	0	1.68	7.2	12.8

^a mg of bentonite per ml of (M.W.R.) serum. ^b Average of 3 determinations

